Tuis207940 • KRX
add
Samsung Biologics Co Ltd
Vorige sluiting
₩1 724 000,00
Dagwisseling
₩1 714 000,00 - ₩1 745 000,00
Jaarwisseling
₩920 000,00 - ₩1 841 000,00
Markkapitalisasie
79,62 bn KRW
Gemiddelde volume
59,83 k
P/V-verhouding
49,89
Dividend-opbrengs
-
In die nuus
Finansieel
Inkomstestaat
Inkomste
Netto inkomste
| (KRW) | Sep. 2025info | J/J-verandering |
|---|---|---|
Inkomste | 1,66 bn | 39,86% |
Bedryfskoste | 245,96 mjd | 21,59% |
Netto inkomste | 574,46 mjd | 117,21% |
Netto winsgrens | 34,60 | 55,30% |
Wins per aandeel | 8,07 k | 41,26% |
EBITDA | 907,77 mjd | 83,24% |
Effektiewe belastingkoers | 25,10% | — |
Balansstaat
Totale bates
Totale aanspreeklikheid
| (KRW) | Sep. 2025info | J/J-verandering |
|---|---|---|
Kontant en korttermynbeleggings | 1,96 bn | 98,36% |
Totale bates | 18,34 bn | 14,42% |
Totale aanspreeklikheid | 6,16 bn | 13,30% |
Totale ekwiteit | 12,18 bn | — |
Uitstaande aandele | 46,29 m | — |
Prys om te bespreek | 6,55 | — |
Opbrengs op bates | 10,09% | — |
Opbrengs op kapitaal | 13,79% | — |
Kontantvloei
Netto kontantverandering
| (KRW) | Sep. 2025info | J/J-verandering |
|---|---|---|
Netto inkomste | 574,46 mjd | 117,21% |
Kontant van bedrywe | 619,30 mjd | -16,36% |
Kontant van beleggings | -213,70 mjd | 51,11% |
Kontant van finansiering | -202,25 mjd | 71,65% |
Netto kontantverandering | 212,65 mjd | 149,08% |
Beskikbare kontantvloei | 333,74 mjd | 2 853,05% |
Meer oor
Samsung Biologics Co., Ltd. is a global contract development and manufacturing organization headquartered in Songdo, Incheon, South Korea. The biotech division of Samsung Group, its core services range from late discovery to large-scale commercial manufacturing. The company focuses on monoclonal antibodies, bispecific antibodies, antibody-drug conjugates, and mRNA vaccines.
The company has partnered with pharmaceutical companies such as Pfizer, GlaxoSmithKline, Eli Lilly, AstraZeneca and Bristol-Myers Squibb. Wikipedia
HUB
Gestig
2011
Webwerf
Werknemers
4 770
